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A B S T R A C T
Background: To describe the prevalence, clinical characteristics, impact of systemic steroids exposure and
outcomes of delayed cerebral vasculopathy (DCV) in a cohort of adult patients with pneumococcal
meningitis (PM).
Methods: Observational retrospective multicenter study including all episodes of PM from January 2002
to December 2015. DCV was defined as proven/probable/possible based upon clinical criteria and
pathological-radiological findings. DCV-patients and non-DCV-patients were compared by univariate
analysis.
Results: 162 PM episodes were included. Seventeen (10.5%) DCV-patients were identified (15 possible, 2
probable). At admission, DCV-patients had a longer duration of symptoms (>2 days in 58% vs. 25.5%
(p 0.04)), more coma (52.9% vs. 21.4% (p 0.03)), lower median CSF WBC-count (243 cells/uL vs.
2673 cells/uL (p 0.001)) and a higher proportion of positive CSF Gram stain (94.1% vs. 71% (p 0.07)).
Median length of stay was 49 vs. 15 days (p 0.001), ICU admission was 85.7% vs. 49.5% (p 0.01) and
unfavorable outcome was found in 70.6% vs. 23.8% (p 0.001). DCV appeared 1-8 days after having
completed adjunctive dexamethasone treatment (median 2,5, IQR = 1.5-5).
Conclusions: One tenth of the PM developed DCV. DCV-patients had a longer duration of illness, were
more severely ill, had a higher bacterial load at admission and had a more complicated course. Less than
one third of cases recovered without disabilities. The role of corticosteroids in DCV remains to be
established.
© 2020 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).
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Streptococcus pneumoniae (Sp) is the predominant causative
pathogen of community-acquired bacterial meningitis (C-ABM) in
adults, causing up to 53% of cases (van de Beek et al., 2016).
Pneumococcal meningitis (PM) is associated with a high mortality
rate (18-26%) and a high rate of neurological sequelae (20-37%) in
surviving patients (van de Beek et al., 2006), (Lucas et al., 2016).
Cerebrovascular complications are associated with poor prog-
nosis and occur frequently during PM, including arterial ischemic
stroke (14 - 25%), cerebral venous thrombosis (1 - 9%), intracranial
hemorrhage (1 - 5%) and cerebral vasculitis (van de Beek et al.,
2016), (Schut et al., 2012), (Vergouwen et al., 2010). After theciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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in adults with PM, a rare cerebrovascular complication character-
ized by an initial good recovery followed by sudden deterioration
several days after presentation has been described. Some cases of
delayed cerebral vasculopathy (DCV) or thrombosis have been
reported (Schut et al., 2009), (Lucas et al., 2013), (Wittebole et al.,
2016), (Gallegos et al., 2018), but studies on its incidence, clinical
spectrum, prognosis and impact of the use of aDXM are scarce.
The aims of the present study were to identify the prevalence of
DCV in a cohort of adult patients with PM, and to describe the
clinical course, the impact of dexamethasone exposure and
outcomes.
2. Methods
2.1. Study design, setting and patients
A retrospective observational multicenter study was carried out
in two acute-care teaching hospitals in Barcelona, Spain, which are
both Neurosurgery referral centers. Hospital Universitari de
Bellvitge (HUB) is a 700-bed teaching hospital (mean annual
admission of 34,000 patients) and the Hospital Universitari Mútua
Terrassa (HUMT), a 400-bed teaching hospital (mean annual
admission of 24,000 patients).
All episodes of PM in adults ( 16 years old) were prospectively
recorded in a database since 1977 in HUB or identified through the
Microbiology Laboratory records in HUMT. All PM cases identified
from January 2002 to December 2015 were included and
retrospectively reviewed.
The following variables were collected: Demographic and
clinical characteristics, radiological, laboratory and clinical find-
ings at admission; antimicrobial treatment and aDXM (duration
and doses); evolution and outcomes. Data were collected from the
medical charts and electronic medical records of both hospitals.
STROBE recommendations (Vandenbroucke et al., 2014) were
followed to strengthen the reporting of the study results
(supplementary material, Table S1).
2.2. Definitions
PM was diagnosed in patients with compatible clinical findings
suggestive of meningitis and 1 or more of the following: positiveTable 1
Pathological and radiological findings established to classify DCV
PATHOLOGICAL-RADIOLOGICAL FINDINGS




PROVEN Compatible biopsy or autopsy
* only one criterion is defining in each section.
DCV: Delayed Cerebrovascular Vasculopathy, CT: Computerized tomography, MRI: Mag
(Calabrese and Mallek, 1988), (Ehsan et al., 1995), (Zuber et al., 1999).CSF culture for Sp, positive CSF Gram stain for Sp, positive CSF
immunochromatographic antigen test for Sp, positive blood
culture for Sp and CSF pleocytosis ( 5cells/mm3).
DCV was defined by a multidisciplinary team based upon clinical
criteria and pathological-radiological findings (Table 1) (Calabrese
and Mallek,1988), (Ehsanetal.,1995), (Zuberet al.,1999).We defined
the clinical criteria of DCV as: (a) clinical worsening after 72 hours of
admission with a new onset of fever and/or neurological symptoms
without an alternative diagnosis, and/or (b) lack of improvement
after 72 h of adequate antimicrobial and corticosteroids treatment
without an alternative diagnosis. The presence of seizures, focal
neurologic deficits, a fall in the Glasgow coma scale (GCS) or death in
the first 72 h were not considered DCV clinical criteria. When clinical
criteria were met, DCV was classified according to the pathological
and radiological findings (Table 1) in proven, probable or possible. (i)
Proven: compatible biopsy or autopsy, (ii) probable: compatible
arteriography, angiography-CT/MRI, (iii) possible: compatible
CT/MRI.
Immunosuppression was defined by the presence of at least one
of the following: infection with the human immunodeficiency
virus, chronic corticosteroid therapy, and use of immunosuppres-
sive agents or biological drugs. Corticosteroid therapy was defined
as > = 5 mg/24 hours of prednisone or an equivalent dose of
another corticosteroid. Comorbidities considered included diabe-
tes mellitus, hepatic cirrhosis, asplenia, and solid and haemato-
logic neoplasm.
Time to admission was defined as the time from onset of
symptoms to the first dose of appropriate antibiotic therapy.
Patients with duration of illness at admission longer than 2 days
were defined as having late presentation. A Glasgow Coma Score
(GCS) < 14 was defined as altered mental status, GCS < 8 was
defined as coma. Cranial computed tomography (CT) was not
routinely performed at admission. Cranial CT or MRI during
admission was performed according to the individual criteria of
each physician at charge.
The lack of improvement after 72 h of appropriate treatment
and the presence of clinical worsening after an improvement were
defined as a clinical complication. Recurrent fever was defined as
fever reappearing after at least 1 afebrile day (Weisfelt et al., 2006).
Outcome and sequelae were graded with the Glasgow Outcome
Scale (GOS) (Jennett et al., 1976), a scale with scores varying from
one to five: 1 = death; 2 = vegetative state; 3 = major disability;Multiple infarctions in different vascular territories
Bilateral infarctions
Lesions in different state of evolution
Multiple hemorrhages (parenchyma and/or subarachnoid)
Bilateral hemorrhages
Coexisting hemorrhagic and ischemic lesions
Blunt lesions
Previous CT findings (more sensitive) + :





Multiple occlusions with sudden stops
Effusion of vascular contour
Alteration of circulation time
netic resonance imaging.
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outcome was defined as a score of 5 and an unfavorable outcome as
a score of 1–4.
2.3. Treatment
Empirical treatment was considered adequate if the antibiotic
used was active in vitro against the strain isolated. Definitive
therapy was penicillin or cefotaxime/ceftriaxone at meningeal
doses or vancomycin, in all cases following the hospital guidelines.
aDXM was defined as the administration of dexamethasone at
admission, before or with the first dose of antibiotic therapy.
In HUB, all patients with suspected PM have been treated since
1987 with aDXM 4 mg/6 h for 48 hours, eight doses in total,Table 2
General characteristics of 162 patients with PM, and comparison between DCV-patient
Variables PM patie
N = 162, N
Age (years), median (IQR) 62 (49-71
Gender, male 88 (54.3)
Recurrent meningitis 17 (10.5)
Source of infection * 
- No identified source 27 (16.7)
- Probable CSF leaks 12 (7.4) 
- Proven CSF leaks 24(14.8) 
- Chronic sinusitis 6 (3.7) 
- Acute sinusitis 8 (4.9) 
- Acute otitis 74 (45.7)
- Pneumonia 8 (4.9) 
- Others 9 (5.6) 
Comorbid conditions
Diabetes mellitus 31/125 (2
Chronic liver disease 11/125 (8
Splenectomy 5/125 (4)
Haematologic neoplasia 17/125 (1
Solid neoplasia 9/125 (7.
Immunosuppression 13 (8) 
Clinical features on presentation
Fever >38 C 121 (74.7
Headache 115 (71) 
Neck stiffness 109 (67.3
Vomiting 82 (50.6)
Duration of symptoms
-<12 hours 42 (26.1)
- 12-48 hours 72 (44.7)
->2 days 47 (29.2)
Score on Glasgow Coma Scale
-<14 (altered mental status) 95 (58.6)
-<8 (coma) 40 (24.7)
Cranial nerve palsies 15 (9.5) 
Hemiparesia 14 (8.7) 
Convulsion 23 (14.4)
Microbiological and biochemical findings at admission
Positive Gram stain 119 (73.5
Positive CSF culture 120 (74.1
Positive blood cultures 119 (73.5
CSF characteristics
WBC count (cells/uL), median (IQR) 2500 (57
Neutrophil (%), median (IQR) 93 (85.5-







Appropiate empirical antimicrobial (AM) treatment 145/147 (
Directed therapy with cephalosporins or penicillin at high doses 154/156 
AM duration (days), median (IQR) 10 (10-14
Adjunctive dexamethasone (DXM) 154/158 
DXM duration (days), median (IQR) 3 (2-5) 
* Numbers do not add up to total because of the presence of multiple sources in severa
Interquartil range, CSF: Cerebrospinal fluid, WBC: White blood cells, AM: antimicrobiabeginning 10–15 minutes before antibiotic therapy with a doubled
first dose.
In HUMT, aDXM 10 mg/6 h for 96 h, beginning 10–15 min before
antibiotic therapy has been administered on suspicion of C-ABM
ever since the publication of the results of a European controlled
trial in C-ABM (de Gans and van de Beek, 2002) in 2002.
2.4. Statistical analysis
All statistical analyses were performed using SPSS, version 15.0
(SPSS Inc., Chicago, Illinois). Categorical variables are presented
using counts and percentages and continuous variables as means





N = 17, N (%)
non-DCV patients
N = 145, N (%)
p
) 58 (45 – 72) 62 (49 -71) 0.81
 10 (56.8) 78 (53.8) 0.69
 4 (23.5) 13 (9) 0.08
0.32
 4 (23.5) 23 (15.9)
3 (17.6) 9 (6.2)
2 (11.8) 22 (15.2)
2 (11.8) 4 (2.8)
2 (11.8) 6 (4.1)
 3 (17.6) 71 (49)
1 (5.9) 7 (4.8)
1 (5.9) 8 (5.5)
4.8) 2/14 (14.3) 29/111 (26.1) 0.51
.8) 1/14 (7.1) 10/111 (9) 1
 3/14 (21.4) 2/111 (1.8) 0.01
3.6) 3/14 (21.4) 14/111 (12.6) 0.41
2) 0 9/111 (8.1) 0.6
3 (17.6) 10 (6.9) 0.12
) 10 (58.8) 111 (76.6) 0.11
10 (58.8) 105 (72.4) 0.24
) 7 (41.2) 102 (70.3) 0.02
 8 (47.1) 74 (51) 0.76
 3 (17.6) 39 (26.8) 0.76
 4 (23.5) 68 (46.9) 0.12
 10 (58.8) 37 (25.7) 0.004
 7 (41.2) 88 (60.7) 0.47
 9 (52.9) 31 (21.4) 0.03
2 (11.8) 13 (9.2) 0.67
2 (11.8) 12 (8.3) 0.65
 1 (5.9) 22 (15.4) 0.47
) 16 (94.1) 103 (71) 0.04
) 16 (94.1) 104 (71.7) 0.07
) 15 (88.2) 104 (71.7) 0.24
6-5650) 243 (97.5-611) 2673 (810-6000) 0.001
96.5) 89 (75-92) 93 (86-97) 0.15
86.5) 15/16 (93.8) 122/142 (85.9) 0.7
0.18
.5) 0 10 (6.9)
9.7) 7 (41.2) 70 (48.3)
5.5) 8 (47.1) 47 (32.4)
.4) 0 13 (9)
98.6) 15/16 (93.8) 130/131 (99.2) 0.21
(98.7) 17/17 (100) 137/139 (98.6) 1
) 15 (10-22) 10 (10-12) 0.025
(97.5) 15/16 (93.8) 139/142 (97.9) 0.35
5 (4-8) 2 (2-4) 0.26
l patients.PM: Pneumococcal meningitis, DCV: Delayed Cerebral Vasculopathy, IQR:
l, DXM: dexamethasone.
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test or Fisher exact test for categorical variables and t-test or
Mann-Whitney test for continuous variables, when appropriate.
Differences were considered statistically significant at the two-
sided p < 0.05 level.
3. Results
3.1. Baseline characteristics
A total of 162 episodes of PM were identified during the study
period,128 in HUB and 34 in HUMT. Seventeen (10.5%) cases of DCV
were identified: 15 (9.3%) were classified as possible and 2 (1.2%) as
probable.
Table 2 shows the epidemiological and clinical characteristics at
admission and the laboratory findings of the 162 episodes of PM, as
well as the comparison between patients with DCV (DCV-patients)
and those without it (non-DCV-patients).
The serotypes identified in both groups were similar.
Cranial CT at admission was performed in 138 (85.2%) episodes
(Table 3). During admission Cranial CT or MRI was performed when
intracranial abnormalities were suspected, in 41/47 episodes
(87.2%). Arteriography or angiography-CT/MRI was carried out in
6/47 cases (12.8%) and 2 of the findings showed compatibility with
DCV. A cerebral biopsy was performed to a patient with clinical and
radiological suspicion of DCV, but DCV could not be confirmed.
3.2. Treatment
Table 2 shows the characteristics of the empirical and directed
antimicrobial treatment and the aDXM treatment. Two cases
received directed therapy with vancomycin: one due to penicillin
allergy and beta-lactam resistance, and the other one due to beta-
lactam resistance (penicillin MIC 2 mg/mL, cefotaxime MIC
1 mg/mL for both cases). 97.5% of cases received aDXM treatment
during a median of 3 days (IQR 2-5), without differences between
DCV-patients and non-DCV-patients.
3.3. Evolution and outcomes
Table 4 shows the evolution and outcomes in the entire cohort
and the comparison between DCV-patients and non-DCV-patients.
There were no meningitis relapses. Patients were followed up 90
days after discharge (median, IQR 39 - 339).Table 4
Evolution and outcome in patients with PM, and comparison between DCV-patients an
Variables PM patients
N = 162, N (%)
Length of hospital stay, median (IQR), days 16 (12 – 26) 
Fever recurrence 47/153 (30.7) 
Neurological complication*: 41 (25.3) 
Stroke 19 (11.7) 
Brain abscess 6 (3.7) 
Venous Trombosis 1 (0.62) 
Subdural empyema 5 (3.1) 
Others & 12 (7.4) 
Intensive Care Unit 80/153 (52.3) 
Mechanical Ventilation 66/153 (43.1) 
Glasgow Outcome Score
- Unfavorable outcome 42/143 (29.4) 
- Favorable outcome 101/143 (70.6) 
Mortality 19 (11.8) 
PM: Pneumococcal Meningitis, DCV: Delayed Cerebrovascular Vasculopathy, IQR: Inter
* Numbers do not add up to total because of the presence of multiple complications
& Seizures 3 (12%), neuritis III cranial nerve 3 (12%), exitus due to meningitis 4 (16%), di3.4. DCV patients
DCV appeared within 4-27 days after admission (median = 7,
IQR = 4.5-8). Referral data from one of the patients was missing. At
the DCV presentation, 3/16 patients (18.8%) were not receiving
antibiotic and in 12/16 (75%) patients aDXM was stopped in the
previous 1-8 days (median = 2.5, IQR = 1.5–5). Targeted treatment
either started or modified for DCV consisted in: (1) antimicrobials in
9/16 patients (56.3%) during 3-44 days (median = 16, IQR = 12-19), (2)
dexamethasone in 14/16 patients (87.5%) during 12-180 days
(median = 39.5, IQR = 16-97), with median doses the first 24 hours
of 16 mg (IQR 9.5-24). Five patients (29.4%) recovered showing no
disability, 2 of them had not been treated with dexamethasone, 10
(58.8%) recovered with major or moderate disability, and 2 patients
(11.8%) died, both under dexamethasone treatment. Description of
DCV-cases is shown in Table 5.
4. Discussion
This is the largest cohort of DCV in adults with PM published to
date, and the first study that evaluates its clinical characteristics,
outcome and relationship with aDXM. Since the use of aDXM was
routinely standardized, some cases of cerebral vasculitis or delayed
cerebral thrombosis occurring after an initial clinical improvement
of the PM have been described (Schut et al., 2009), (Lucas et al.,
2013), (Wittebole et al., 2016), (Gallegos et al., 2018), (Lefebvre
et al., 2007), (Pugin et al., 2006), (Katchanov et al., 2010), (Rice
et al., 2012), (Regaieg et al., 2016), (Ribeiro et al., 2013), (Darling
et al., 2012). However, neither this clinical entity nor the role of
aDXM or treatment with corticosteroids has been defined.
Our study shows that DCV is not uncommon; more than one
tenth of adults with PM showed clinical worsening after systemic
steroids discontinuation, developing a probable or possible DCV.
There were no differences in demographic characteristics
among DCV-patients and non-DCV-patients. No populations at
risk of developing DCV could be identified due to the small sample
size, but in the DCV-group there were more underlying conditions
that may predispose either to develop PM (splenectomy (21.4%)
and recurrent meningitis (23.5%)) or to orchestrate an inadequate
immune response (haematologic neoplasia (21.4%) and immuno-
suppression (17.6%)). Remarkably, there were less DCV-cases when
the source of infection was an acute otitis. There were no more
pathological findings in CT at admission, showing that DCV appears
later in the course of the disease.d non-DCV-patients
DCV patients
N = 17, n (%)
Non-DCV patients
N = 145, n (%)
p
49 (31 - 62) 15 (11 - 23) 0.001
11/16 (68.8) 36/137 (26.3) 0.001
17 (100) 24 (16.6) 0.001
17 (100) 3 (2.1) 0.001
1 (5.9) 5 (3.4) 0.49
0 1 (0.69) 1
1 (5.9) 4 (2.8) 0.43
0 12 (8.3) 0.22
12/14 (85.7) 68/139 (49.5) 0.010
10/13 (76.9) 56/140 (40) 0.017
12/17 (70.6) 30/126 (23.8) 0.001
5/17 (29.4) 96/126 (76.2) 0.001
2 (11.8) 17 (11.8) 1
quartil range.
 in several patients.
sseminated acute encephalomyelitis 1 (4%), Raeder paratrigeminal syndrome 1 (4%).
Table 5
Description of DCV patients
Case Sex/Age Serotype& Comorbidities Days to
DCVa




1 Male/37 23A SP, LC, IS 4 RF ATB 4d, aDXM 4d ATB 15d CT, MRI 5
2 Male/72 4 – 5 RF, FNA, AMS ATB 5d, aDXM 5d ATB 9d, DXM 13d CT, MRI 3
3 Male/39 19F – 12 PF, FNA ATB 11d, aDXM 6d ATB 44d, DXM 77d CT 4
4 Male/45 9V – 4 C, AMS ATB 4d, aDXM 2d ATB 6d, DXM 16d CT, MRI 4
5 Male/59 19a – 12 RF, FNA, Cv ATB 11d, aDXM 12d ATB 9d, DXM 23d MRI 5
6 Female/
57
NA – 7 RF, FNA, AMS ATB 7d, aDXM 2d ATB 11d, DXM 15d CT, MRI 3
7 Female/
37
15C – 4 AMS ATB 4d, aDXM 2d ATB 11d, DXM 56d MRI 4
8 Female/
69
– – – – MRI 3
9 Male/53 10a SP, HN, IS 4 AMS ATB 4d, aDXM 3d ATB 6d, DXM 63 CT, MRI 1
10 Female/
73
19a – 6 RF ATB 6d, aDXM 4d ATB 8d, DXM 17d MRI 5
11 Male/50 12F SP 8 RF, Cv ATB 8d, aDXM 4d ATB 16d, DXM 180d CT 4
12 Male/63 1 HN 10 FNA, AMS ATB 10d, aDXM 7d ATB4d, DXM 97d MRI 5
13 Female/
75
3 DM 6 RF, FNA, AMS ATB 6d, aDXM 5d ATB 12d, DXM 8d MRI 1
14 Female/
36
23A HN, IS 27 RF, FNA, Cv ATB 23d, aDXM 27d ATB 3d, DXM 180d MRI, angio-MRI 3
15 Female/
87
3 – 7 C, FNA, Cv ATB 7d ATB 19d, DXM 103d MRI, angio-MRI 4
16 Male/74 16F DM 7 RF, AMS ATB 7d, aDXM 6d ATB 3d, DXM 13d MRI 4
17 Male/65 13 – 8 PF ATB 8d, aDXM 3d ATB 11d MRI 5
DCV Delayed Cerebral Vasculopathy, DM diabetes mellitus, SP splenectomy, LC liver cirrosis, HN haematologic neoplasia, SN solid neoplasia, IS immunossuppresion, PF
persistent fever, RF recurrent fever, C cephalea, FNA focal neurological abnomalities, Cv convulsion, AMS altered mental state, ATB antibiotic, aDXM adjunctive
dexamethasone, DXM dexamethasone (or equivalent treatment with other corticosteroid), CTcranial computed tomography, MRI cranial magnetic resonance imaging, d days.
& Serotyping was performed by Quellung reaction at the Spanish Reference Laboratory.
a Days from admission to DCV.
b Clinical features at presentation of DCV.
c Treatment received for pneumococcal meningits until DCV.
d Treatment started or continued for DCV.
* Glasgow Outcome Scale (GOS): 1 = death; 2 = vegetative state; 3 = major diability; 4 = moderate disability; 5 = good recovery, no disability.
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more severely ill at admission as measured by the GSC. A decreased
level of consciousness at admission has been previously described
as a factor predicting the development of cerebral infarction (Schut
et al., 2012), (Katchanov et al., 2010) and unfavorable outcome
(Weisfelt et al., 2006), (Kastenbauer and Pfister, 2003).
Regarding CSF characteristics, a lower median of WBC count
(243 vs. 2673/mm3) and a higher proportion of positive Gram
stains (94.1% vs. 71%) and culture (94.1% vs. 71.7%) were observed in
DCV-patients. As previously described, a low CSF leucocyte
response has been associated with immunodeficiency, high
bacterial growth in CSF, development of ischemic cerebrovascular
complications and with unfavorable outcome (Weisfelt et al.,
2006), (Katchanov et al., 2010), (Kastenbauer and Pfister, 2003).
This lower WBC count and the higher proportion of positive Gram
stain and culture in CSF could suggest a milder inflammatory
reaction and a higher bacterial load.
Cranial CT/MRI was performed when neurological complica-
tions were suspected. However, arteriography or angiography-CT/
MRI were only performed in 12.8% of cases and only one biopsy
was done. Consequently, 88.2% of DCV-cases were classified as
possible, 11.8% as probable, and there were no proven cases. A
higher clinical suspicion could have improved the diagnostic yield.
In our opinion, clinical worsening without an alternative
diagnosis after having stopped dexamethasone, should prompt
the performance of an angio-CT/MRI.
DCV-patients experienced a more complicated course, as
evidenced by a longer hospital stay, greater need for ICU admission
and mechanical ventilation. They had more sequelae as measured
by the GOS, and showed a 70.6% of unfavorable outcome.
Surprisingly, there were no differences in mortality, perhapsattributable to the small sample size and the low fatality rate of our
cohort.
Since 2002 aDXM is currently routinely used in the treatment of
adults with PM after evidence from previous studies showing that
corticosteroids reduced mortality in PM in high-income countries
(de Gans and van de Beek, 2002), (Brouwer et al., 2015).
Little is known about the current prevalence of DCV in PM, since
most reports on cerebrovascular complications described cohorts
older than 2002 (Schut et al., 2012), (Vergouwen et al., 2010),
(Kastenbauer and Pfister, 2003), before the routine use of aDXM.
Some papers published later do not show a clear correlation
between the use of aDXM and the development of cerebrovascular
complications (Katchanov et al., 2010), (Bodilsen et al., 2014) or
they do not make reference to the use of dexamethasone (Mook-
Kanamori et al., 2012). Therefore, data on the long-term effect of
dexamethasone in PM are lacking and information on the impact of
the use of dexamethasone on cerebrovascular complications is
scarce.
In 2009, Schut et al reported 6 patients with a devastating
delayed vasculopathy complicating C-ABM after dexamethasone
withdrawal (Schut et al., 2009). They described this new entity as
delayed cerebral thrombosis (DCT) because they found an arterial
thrombosis in one patient autopsy, but no evidence of vasculitis.
Since then, DCT has been reported in 20 patients, with a prevalence
of 1 - 4.1% (Lucas et al., 2013), (Wittebole et al., 2016), (Gallegos
et al., 2018). On the other hand, some cases with a delayed clinical
worsening related to the presence of cerebral vasculitis have also
been published (Lefebvre et al., 2007), (Pugin et al., 2006), (Rice
et al., 2012), (Regaieg et al., 2016). However, the pathological
substrate of both thrombosis or vasculitis has not been consistently
demonstrated.
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the authors found inflammation in the meninges and blood
vessels with extensive infarction and thrombosis. However, there
were no differences between patients with delayed clinical
worsening and those without it (Engelen-Lee et al., 2018).
Therefore, it seems that DCV is a clinical entity that can be
caused by different vascular complications like thrombosis,
vasculitis, disseminated intravascular coagulation, vasospasm
or rebound effect of the primary inflammatory response after the
withdrawal of steroids.
In this sense, some authors have suggested a gradual steroid
withdrawal rather than the abruptly terminated 4-day course
currently advocated, or a longer treatment with progressive
tapering (Lefebvre et al., 2007), (Rice et al., 2012) in order to
avoid a “rebound effect” secondary to stopping corticosteroid
therapy. Recently, a retrospective study investigating the
prevalence of DCV in patients with C-ABM showed that aDXM
was more likely given to DCV-patients (100% (5/5) vs 37.5%
(43/115) in non-DCV-patients) (Gallegos et al., 2018). However, the
results must be interpreted with caution, as they only had 5 DCV-
patients and the proportion of patients treated with aDXM in the
whole cohort was low (40%). In our study, an association with
aDXM was difficult to prove due to the high proportion of
compliance with steroids (97.5%).
No randomized clinical trials addressing the benefits of
different timings of corticosteroid therapy have been performed
in adults. In our study, patients received a shorter aDXM treatment
than the recommended one in guidelines, with a median duration
of 2 days. Despite receiving a lower dose of corticosteroids, the rate
of neurological complications has been 25.3% and mortality rate
11.8%, less than the figures reported in recent literature (Engelen-
Lee et al., 2016). This dosage of aDXM has previously shown to be a
protective factor in elderly patients with PM (Cabellos et al., 2009).
Remarkably, the proportion of DCV was higher in HUMT (23.5% vs.
7.03%, p 0.005), where corticosteroids were prescribed as
recommended in guidelines.
There is no evidence about who would benefit from corticoste-
roids reintroduction after worsening. In our study, dexamethasone
was reintroduced as DCV-treatment in 87.5% of patients with
heterogenous results.
Our study has some strengths: it is the largest cohort of DCV in
adults published to date and shows a higher prevalence (10.5%). It
represents a very homogeneous group: aDXM and appropriate
empirical antimicrobial therapy were administered to most of the
cohort. Clinical characteristics, outcome and the role of aDXM have
been thoroughly investigated and described. Finally, an effort to
define the diagnostic criteria of DCV by a multidisciplinary team
has been attempted for the first time.
Main limitations of our study are: (a) it is a retrospective
observational study; (b) CT was not performed systematically at
admission or whenever patients had neurological complications,
and this could have led to an underestimation of the prevalence of
DCV. The poor performance of angiographic imaging may have
underdiagnosed and misclassified DCV-cases. (c) The sample size
did not allow us to identify strong correlations. Finally, our study
was conducted in a specific geographical area, and the results
cannot be extrapolated to other settings.
The prevalence of delayed cerebral vasculopathy is relevant,
with more than one tenth of the PM developing a probable or
possible DCV. Patients that developed DCV presented a more
severe illness, lower inflammatory CSF response and higher
bacterial load at admission. DCV is a severe neurological
complication, as reflected by a longer hospital stay, greater need
for ICU admission and more sequelae, with more than two thirds of
unfavorable outcomes. The role of corticosteroids in DCV and their
dosage remain to be established.Funding
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